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Introduction

Evidence, including the recent findings of the START study,
shows the overwhelming success of early HIV treatment in
lowering the risk of developing AIDS as well as preventing
HIV transmission.2 Access to antiretroviral therapy (ART) has
improved significantly in recent years. At the end of 2013, there
were 12.9 million people receiving ART, with 5.6 million of
those added since 2010.3 Nonetheless, at the end of 2013 only
37% of people living with HIV were receiving treatment, leaving
22 million people in need of ART.4 In 2014, UNAIDS set the
90-90-90 target – an “ambitious but achievable” goal toward
ending the AIDS epidemic by 2030 (see Box 1).
The 90-90-90 target focuses on equity; UNAIDS notes “it will
be impossible to end the epidemic without bringing HIV treatment to all who need it.”5 This brief demonstrates how gender
dynamics impact HIV treatment access and adherence and illustrates how greater attention to these dynamics within HIV interventions can improve treatment uptake and adherence critical to
achieving the 90-90-90 goal. This brief uses WHO’s HIV care
cascade as a useful framework within which to view the evidence
regarding how gender dynamics help or hinder HIV treatment
efforts (see Figure 1). This brief also identifies priority actions
needed for gender-equitable treatment programming to achieve

About this brief
This brief provides policymakers and program implementers
with evidence about the impact of gender dynamics on
treatment access and adherence and the gender-related
gaps in treatment research and programming. It also
includes priority actions that can be taken to better address
gender within treatment programming and raises questions
for implementation science in order to achieve the global
90-90-90 goals (see Box 1). This brief draws from What
Works For Women and Girls: Evidence for HIV Interventions
(www.whatworksforwomen.org) and uses the WHO treatment
cascade framework to identify and analyze major gender
considerations in providing antiretroviral therapy to those
living with HIV in low- and middle-income countries. It
focuses on antiretroviral treatment access and adherence as
well as the gender dynamics related to who gets tested and
under which circumstances. The brief does not cover the full
provision of “HIV care” defined in the cascade to also include
prevention, detection and treatment of co-infections such
as TB, as well as nutrition and social support.1 For more on
gender dynamics within those topics and to read about the
full methodology for the evidence review, please see www.
whatworksforwomen.org.
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to afford the time or money required to travel to a facility
providing HIV testing. In some places, high rates of
illiteracy mean that many women cannot access written
information about the benefits or availability of HIV testing.
Stigma, gender inequalities, and fear of negative outcomes
following disclosure are significant barriers. Such outcomes
include moral judgment and blame; ostracism by household
or community; relationship termination; verbal and/or
physical abuse as well as discrimination. In many countries,
women living with HIV are spoken of as being promiscuous
women who deserve this disease as a punishment for their
sins.9 Fear of stigma and discrimination from health care
providers is also a concern, especially for women from
marginalized groups such as those who are sex workers or
transgender.

Box 1

90-90-90 Target
By 2020:
• 90% of all people living with HIV will know their
HIV status.
• 90% of all people with diagnosed HIV infection
will receive sustained antiretroviral therapy.
• 90% of all people receiving antiretroviral therapy
will have viral suppression.
Source: UNAIDS, 2014

the 90-90-90 goal. Given that there are few evaluated gender
interventions for HIV treatment, these priority actions,
along with additional questions for implementation science,
are based on programmatic and technical expertise, as well
as a review of the literature. The actions can be carried out
at multiple levels such as at the community, clinic and policy
levels and, though far from a comprehensive list, illustrate how a gender lens can be useful in ensuring equity in
treatment access and adherence. Further dialogue, research,
programming, and importantly – evaluation – is needed with
input from multiple stakeholders.

Gender Norms Affect Men As Well as Women
Men, too, must overcome barriers to testing. A study
in Lesotho found that there was better access to testing
for women and a strong fear of testing among men.10
Global attention has focused often on prevention of
vertical transmission,11 putting men simply in the role of
supporting access to services for their female partners
living with HIV, rather than caring for their own needs. In
Figure 1

Gender Dynamics within the
Care Cascade

HIV Care Cascade

Knowing One’s HIV Status
There are often gender differences in who gets tested and
why. A review of the literature on studies conducted in rural
India from 1980 to 2008 found that men sought testing
because they were personally concerned, whereas women
sought testing upon the recommendation of their antenatal
provider - and in some cases reported mandatory testing
by their provider.6 Most women access HIV testing within
maternal health services. Since they come into contact with
the health system regularly, pregnant women are disproportionately tested for HIV.7 A 2009 study in rural Mozambique found that HIV testing in non-pregnant women was
“uncommon.”8 The emphasis on counseling and testing
for prevention of maternal to child transmission (PMTCT)
means that women who are not pregnant are inadequately
reached with HIV testing and counseling services.
Women must navigate a number of hurdles in accessing
testing. Many women, especially rural women, are unable

Focus of this brief
Source: WHO, 2015
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families, losing their property, and suffering violence and
abuse. As noted by Jürgens and Cohen, “efforts to increase
access to HIV testing must be accompanied by vastly
scaled up efforts to confront the stigma and human rights
abuses that deter people from seeking HIV tests in the first
place….”18

Box 2

Why is sex- and age-disaggregated data
important?
Because it helps identify gaps in treatment
programming.

Priority Actions for Programming and Policy

For example, of 10,000 people on treatment in
Malawi (Makwiza et al., 2008):

■■ Expand

coverage to reach more women
——Expand coverage of HIV testing and counseling both within and outside of antenatal care
settings.

• More men than women accessed treatment in
the 15-19 year age group, yet HIV prevalence in
this age group was higher among women.

■■ Link

ART services with gender-based violence
services
——Strengthen referral programs for testing and
ART services with services for gender-based
violence.

• More women than men accessed treatment in
the 30-39 year age group, yet HIV prevalence
was higher among men in this age group.
Without sex- and age-disaggregated data, these
inequities are masked under one number: “10,000
on treatment” and critical programming gaps would
remain unnoticed.

■■ Reach

men
——Promote campaigns that counter the harmful
gender norm that “real men don’t get sick”;
promote positive images of men using health
services for the benefit of themselves, their partners, and their families.

many areas of the world, HIV is seen as a threat to a man’s
masculinity, “requiring him to seek care, challenging his
notions of fearlessness, and fueling fears of humiliation
and that his wife will desert him.”12 Men also may worry
that they acquired HIV from extramarital partnerships and
may therefore be less likely to disclose their HIV-positive
serostatus to their spouse13 or to want to get tested in the
first place.

■■ Create

programs to reach men as independent
users of health services rather than exclusively
through their female partners, both for testing
and for treatment
——Create testing programs for male clients of sex
workers with linkage to treatment.

A study in South Africa—where counseling and testing for
HIV is most frequently accessed in antenatal care settings
and a few stand-alone centers14 —found that men rarely
initiate discussions with their female partners concerning
HIV testing and mostly relied on female partners to test
as a means of determining their own HIV status, not
understanding that sexual partners who are serodiscordant
can exist.15 Focus group discussions with young men
in Malawi and Uganda found that gender norms, such
as equating masculinity with invulnerability and sexual
conquest, were the reasons they would not access HIV
testing and counseling.16

■■ Strengthen

couples testing
——Revise national and local guidelines to include
a context-appropriate definition of a “couple,”
gender-sensitive ways to engage men and women
in counseling, and linkages to available gender-based violence services, when needed.

■■ Reach

youth
——Create opportunities for testing with linkage to
treatment services in schools and universities in
order to reach young men and young women
prior to their first pregnancy.

Questions for Implementation Science

Addressing gender norms that suggest that ‘real men do
not get sick’ will be critical to increasing HIV testing and
counseling by men, as well as creating more opportunities
for men to get HIV testing and counseling.17 Rapid
expansion of testing, however, without ensuring informed
consent and confidentiality could increase the risk of
women and transgender people being rejected by their

■■ How

can the number of men as users of health
services – particularly for testing and treatment – be
increased?
■■ How can stigma be reduced to encourage greater
uptake of HIV testing?
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Enrollment in ART & Treatment Care*

interpreted in some countries as a requirement that a man
be present to access treatment. Some women instead choose
to hire men to pose as their male partners: “Because when
you go to antenatal you are asked to come with your partner,
women have chosen to hire boda boda (motorcycle taxi
drivers) to go with them to access the services.”25 Priority
for treatment access to pregnant women creates problems
within relationships: “Actually, the first time I was told about
Option B+, the first question I remember I asked was ‘what about
the man?’ Why did I ask this? Because I really saw that there were
going to be conflicts of interest because men are going to now say, ‘Why
women? Aren’t we also human beings?’” Or as another woman
put it: “Men will say, ‘It’s me who made that woman pregnant. Why
am I not started on treatment too?’”26

Gender norms affect treatment access for men and
women. Women constitute a higher proportion of those
receiving ART than men. For all low- and middle-income
countries, women constitute 51% of those eligible for care
but make up 59% of those receiving ART.19 However,
while more women than men have accessed treatment
globally, structural factors and traditional gender norms can
jeopardize women’s adherence, retention in care or ability to
reduce transmission.
“Women are often more likely than men to attend health
services because of dedicated provision of reproductive
and child health clinics.”20 Many women are first tested
and then put on treatment with the goal of prevention of
vertical transmission. But inadequate attention is given to
the treatment needs of women outside of this scope. The
new WHO guideline recommending Option B+ allows
pregnant women living with HIV to remain on treatment
for life following their pregnancy. But the word “option” is
a misnomer – it is an option for the country, not necessarily
for the pregnant women. In a study in Malawi and Uganda,
pregnant women were told they could have less than 24
hours to consider whether to go on treatment for life – a
weighty decision. As one woman put it: “I’m 18 years, you
are telling me drugs for life?”21 In addition, the focus has been
on prevention of vertical transmission, or as one woman
living with HIV states: “The doctors say, ‘Listen, we are not giving
you these ARVs to save you, we are saving the baby….’’”22 It is
not surprising, therefore, that there are high dropout rates
from treatment programs postpartum, including Option
B+.23 In several countries, Option B+ rollout “has been
characterized by high levels of ‘loss to follow up’ and lower
rates of adherence.”24

Men Often Enroll in ART Later than Women
The Institute of Medicine notes that for PEPFAR data,
each year there were more initial enrollments in ART among
women than among men; the proportion has remained
steady over time at about 65% of women and 35% of
men. This imbalance is greater than the difference in HIV
prevalence between men and women.27 Patient data from
307,110 adults from Kenya, Mozambique, Rwanda and
Tanzania between 2006 and 2011 found that risk of late
enrollment (CD4 counts under 350) was significantly higher
for men and nonpregnant women as compared to pregnant
women.28
Harmful gender norms (e.g., viewing seeking health care as
weakness) frequently cause men to delay presentation for
treatment, which can reduce their life expectancy. A study
of 4,775 patients from Uganda found there was a higher
death rate for men, even when the analysis included women
who accessed ART outside of ANC services, with more
men presenting for care with lower CD4 counts, with single
men having significantly lower CD4 counts than married
men or single women.29

In addition, male involvement in Option B+ has been
* Note that this brief focuses on antiretroviral therapy and does not fully
cover all aspects of treatment care such as treating co-infections and
provision of nutritional and social support.

“…Although women remain more vulnerable to HIV
infection, once infected, men tend to be disadvantaged in
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Meanwhile, men are the ones who consider whether or not to take
the drugs because they don’t need to think of anything else except
themselves.”43 Greater attention needs to be paid to ensuring
that men living with HIV know their serostatus, have
access to condoms, understand the need for consistent and
correct condom use, and have equitable access to treatment.
“Closing the coverage gap in men needs to be a priority to
tackle health-related gender inequalities, improve overall
health in men, and decrease transmission….”44

terms of access to treatment and care.” In many countries,
men initiate treatment later, are more likely to be lost to
follow up, and have higher mortality rates.30 Focus group
discussions with men in Uganda found that men found it
difficult to seek treatment, which contradicted their assumed
masculine autonomy and superiority.31
A global review based on 36 studies in resource-rich and
resource-limited settings found that being a heterosexual
male was a consistent risk factor for presenting with low
CD4 counts, resulting in less favorable outcomes for men
once enrolled in treatment.32 In South Africa in 2011, the
fraction of ART-eligible women who were receiving ART
(65%) was significantly higher than the fraction of ARTeligible men who were on treatment (41%).33 An analysis
of 23 cohort studies from Africa, including 216,008
participants found that only 35% of those accessing
ART were men, despite an HIV prevalence of 40%,
representing “a significant underrepresentation of men in
ART programs.”34 In addition, the risk of death for men
was 1.37 times higher than for women.35 However, men are
seldom targeted as they are not often classified as vulnerable
or marginalized.36 While this inequitable access for men to
ART may be due, in part, to a focus on maternal health,
equitable access to ART for men “should be conducted
without …threatening HIV…treatment for women.”37

Inequitable Access to ART Also Differs by Age and
Social Status
Some studies have found that equity in access differs by
age group with inadequate treatment access for adolescent
women. In Malawi, for example, of 10,000 people on
treatment, proportionately more women accessed treatment
than men. However, in the 15 to 19 year age group, more
men were proportionately on treatment despite the fact
that HIV prevalence in this age group was higher among
women.45 “Despite the growing number of older children
and adolescents who develop symptoms, there has been
little focus on providing this group with specialized HIV
care.”46 Providers need training to provide nonjudgmental
care. Instead, one study found that providers would say to
adolescents living with HIV: “You are HIV-positive. You are not
expected to have sex. You are not expected to have a baby.”47

A study of sex differentials in ART uptake in Zambia found
that men were more likely to refuse ART even though men’s
self-rated health was lower than women’s, with norms of
masculinity presenting the biggest barrier for male uptake
of ART.38 Other studies have found that men who received
treatment39 were more likely to die than women because
of late presentation for treatment or were frequently lost
to follow up.40 A study of programmatic data on 334,557
adults enrolling in HIV care at 132 facilities in Kenya,
Mozambique, Rwanda and Tanzania found that men were
1.6 times more likely to initiate ART with advanced HIV
disease (CD4 count under 100) compared with women and
that “this disparity seems to be widening….”41 A recent
study found that men used their economic and decisionmaking power to informally access ART in order not
to be seen at clinics, which are seen as a woman’s space.
Out of shame, men suffered silently and attempted to
cope by stealing their wives’ ARVs. The practice of men
stealing ARVs from their wives endangers both partners,
jeopardizing women’s adherence.42

Transgender people are marginalized and subject to
stigma, violence and social exclusion,48 which can affect
treatment access and adherence. Similarly, sex workers
– who are, worldwide, mostly women49 and among the
most marginalized of women50 – face barriers in accessing
treatment due to stigma, discrimination and social
exclusion.† Importantly, WHO notes that key populations
should have the same access to ART and care and the
same ART management as other populations, “[h]owever,
because of stigma, discrimination and marginalization,
they frequently present late for treatment.”51 Thus, ART
programming that respects human rights is critical - for key
populations, as for all.

Priority Actions for Programming and Policy
■■ Strengthen

services
——Ensure that all service providers are trained in
the principles of non-discrimination to ensure
that people of different gender identities can
access quality services with respectful treatment,
counseling and support.

Gender norms of female submissiveness and women as
caretakers may be critical also for the higher uptake of
ARVs by women, as explained by one Vietnamese woman
living with HIV: “Women have no choice but to take the drugs.

†
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While transgender issues are raised throughout this brief, a full discussion of the barriers to treatment by sex workers, people who use
drugs and other key populations is beyond the scope of this brief.
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——Identify

avenues to provide treatment to women
outside of antenatal care services to reach women who are not pregnant.

reported that they were not allowed to join networks of
people living with HIV who gained access to valuable
support and information services because they were seen as
“social evils” rather than “innocent wives getting the disease
from their husband.”56

■■ Reach

men
both an inclusive atmosphere as well as
physical space within clinics where men can initiate ART with follow up within communities and
with male peer support.

——Create

Other Life Activities Affect Women’s Adherence
Pregnancy represents an additional sex-related factor in
treatment. In a study of 4,531 women from numerous
treatment sites in Sub-Saharan Africa, one-third experienced
a pregnancy within four years of ART initiation.57 Yet few
treatment programs are designed with the likelihood of
pregnancy in mind.58 Most of the world’s women living
with HIV are of reproductive age and will need either
contraception or discussions on how to become pregnant
while reducing the risk of HIV transmission to their infants
and/or partners.

■■ Reach

youth
——Create services that will reach adolescent girls
living with HIV, particularly those under age 18
who will not be reached through pediatric services yet are not comfortable in adult settings.
——Create

sustainable adolescent friendly HIV services that also meet reproductive health needs.

■■ Review

data
——Analyze HMIS data on an ongoing basis to assess
gender equitable access, adherence, and retention
to ensure that care and treatment services are
reaching people in proportion to the burden of
the epidemic.

Side effects can also deter women from adhering to
treatment plans. Some medications cause a redistribution
of body fat resulting, for example, in a large belly, or a
collection of fat at the base of the neck, or loss of fat
from the cheeks.59 Women have reported problems with
adherence due to how ARVs changed their appearance,
with bodily changes creating visibility of their HIV-positive
serostatus and consequent stigma. Women may also be more
adversely affected by the common side effects of ARVs that
result in anemia.60 A study of quality of life among people
living with HIV in Cuba found that pain interfered more in
women’s lives than in men’s lives, and that women did not
enjoy the same health-related quality of life as men.61 In
Vietnam, men, even if they injected drugs, reported better
quality of life on antiretroviral therapy than did women, as
women cared for the men.62

Questions for Implementation Science
■■ How

can men’s engagement with health and ART
services be fostered without interfering with
women’s decision-making and autonomy?
■■ How can treatment programming reach those who
have not yet been reached?

ART Retention
For the most part, men and women have similar ART
adherence rates. But there are gender differences in
predictors of adherence. Women may need family support,
including redistribution of household responsibilities, to
enable them to adhere to treatment. Even if drugs are free
or subsidized, women may not be able to afford the time
or money required to travel to a clinic. A qualitative study
of women living with HIV in Colombia found that women
prioritized the needs of their HIV-positive children over
their own adherence needs.52 Women in Malawi and Uganda
also reported financial and other challenges in managing
their own adherence as well as that of their children.53
Some women sold their ARVs for economic survival.54
Women may also have difficulty navigating treatment when
it conflicts with other activities for survival. Sex workers, in
particular, face difficulties in adherence in large part due to
stigma and discrimination. One South African sex worker
points out the struggles she faces: “If you don’t pay off the
police, they take you to jail…you can’t take antiretroviral drugs or
any medication you need.”55 Female sex workers in Vietnam

Men’s Sense of Masculinity Can Affect Treatment
Adherence
Men also face particular challenges in accessing and adhering
to HIV treatment. Men’s ideal sense of masculinity may
be threatened by “disclosing their HIV status and seeking
treatment in fear that they would be perceived as failing
sons, husbands or breadwinners….”63 A study of men in
Uganda found that adherence challenged gender norms of
masculinity, with men reporting that nurses scolded them:
“It involves being shouted upon like a child, don’t you see, no respect
at all.”64 Being physically strong, capable of hard work and
having children were also seen as signs of masculine identity,
which were threatened by being labeled HIV-positive. A
study from South Africa found that men’s adherence was
challenged by employment, with problems getting time away
from work for clinic visits or loss of income due to waiting
in clinic lines.65

6

Gender Considerations Along the HIV Treatment Cascade: An Evidence Review with Priority Actions

© 2010 Robyn Iqbal, Courtesy of Photoshare

Treatment may be undertaken by some men to regain health
and self-worth with the ability to work and provide for their
families as a sign of their masculinity.66 In one South African
study, when men were not yet on ART but diagnosed with
HIV, family members withdrew support and care, as family
members feared acquiring HIV. Once on ART and feeling
physically well, men felt prepared to withstand potential
rejection as well as confident to look for a girlfriend if a
partner rejected them for their positive serostatus.67
Support groups and counseling for men may also be
beneficial and men do request them.68 Focus group
discussions in South Africa with men living with HIV
on treatment who had disclosed to their partners found
that they wanted to access male-only support groups with
guarantees that their HIV status would not be disclosed
outside of the support group setting. Despite the fact that
support groups were available four times per week, men did
not know of these support groups,69 which met at clinics
where they collect their medication. In Uganda, men who
were recipients of financial support, such as expenses for
children’s education or given livelihood options, such as
goats, were more adherent than men without this support.70

to HIV disclosure.75 Because women are tested for HIV
at much higher rates than men, any approach that blames
women living with HIV for not disclosing their status will
disproportionately burden women. Where male partners
have been unwilling to get tested for HIV, some women
living with HIV did not feel an obligation to disclose their
positive serostatus.76 Women “reflected upon the fact that
men seemed unwilling to test but preferred to blame their
female partners.”77 In some cases, women are significantly
less likely to know their partner’s status than men.78 And one
study of women living with HIV in South Africa found that
consistent condom use was not correlated with disclosure
to either HIV-negative or HIV-positive male partners.79
For women living with HIV, “it is ultimately the decision
of the man to either use a male condom or not,”80 with
gender norms on sexuality key to male use of condoms.
Some evaluated interventions exist regarding women’s
use of female condoms in the absence of male condom
use. However, “ …limited access to female condoms and
substantially higher costs have limited uptake and use of
female condoms,”81 thus limiting an opportunity to reduce
HIV infection through a woman-initiated prevention
method.

Stigma and Gender Norms Can Make Efforts
to Encourage Retention and Reduce HIV
Transmission Difficult
Non-judgmental, non-stigmatizing interventions both
within the health sector and outside the health sector, such
as transforming gender norms, reducing violence against
women, revising laws that criminalize non-disclosure of
HIV, to name a few,71 need to be implemented in order to
support safer sexual behavior once someone knows his or
her positive serostatus.
Some serodiscordant couples identify fear of transmission
as a primary concern in their relationships or fear the impact
that disclosure will have on the HIV-negative partner.72 A
study in South Africa found that among 413 men living
with HIV and 641 women living with HIV, stigma and
discrimination was associated with non-disclosure and that
non-disclosure was associated with HIV transmission risk
behaviors.73
“Persistent rates of nondisclosure by those diagnosed with
HIV raise difficult ethical, public health and human rights
questions about how to protect the medical confidentiality,
health and well-being of people living with HIV on the
one hand, and how to protect partners and children from
HIV transmission on the other.”74 Criminalization of
transmission and nondisclosure undermines rights while
serving little public health benefit, but gender issues are key

Transgender people can face a double stigma for their
gender as well as for their positive serostatus, making
accessing needed health and HIV services, which usually
operate on strict male/female gender identities, extremely
difficult. They are often overlooked in HIV treatment
programming.
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Priority Actions for Programming and Policy
■■ Provide

information and support
——Within all treatment programs, counsel both men
and women on their options if they want to become pregnant/have a child or avert unintended
pregnancies.
——Create

sex-segregated ART support groups, similar to the mothers2mothers model for pregnant
women, for all who are living with HIV.

——Strengthen

training for counselors and other
healthcare workers providing guidance on safe
disclosure for both men and women (separate
guidance for each, address gender issues for
each).

Fear of Disclosure Impacts ART Retention and
Transmission Reduction Efforts

——Provide

services that are user-friendly such as
with on-site childcare or at times or locations that
are women- men- and family-friendly.

Disclosure is not a one-time event but a process calling for
careful consideration as to whom to disclose and when. A
study in Zimbabwe of 200 women living with HIV on ART
found that 96.5% disclosed to at least one person, most
frequently their sister.82 Both women and men need to learn
how to negotiate safe sex prior to disclosure, knowing when
to disclose and how to disclose. Women in one study noted
that once they disclosed, no man had stayed with them.83 In
another study in Uganda, “the need to provide for children
was a particularly strong motivation for women to avoid
disclosure,”84 as men abandoned or abused partners who
disclosed or requested condom use. One cross-sectional
survey in Cameroon found that women living with HIV who
were not financially dependent on their male partners were
much more likely to have used condoms,85 suggesting the
importance of the enabling environment.

■■ Address

legal barriers
——Create or strengthen programs for the judicial
sector to ensure ART is available within jails,
prisons, etc. and that those living with HIV taken
into custody can adhere to ART. (This is particularly important for sex workers).
——Decriminalize

HIV transmission, which can be
particularly harmful to women and may criminalize vertical transmission during pregnancy.

■■ Analyze

gender dynamics
——Review and design programs to ensure that they
are based upon a gender analysis and address
harmful gender norms and gender-based violence and are evaluated to better elucidate how
a gender-sensitive approach affects treatment
adherence and retention.

A study in South Africa found that for men, disclosure
undermined their sense of masculinity as health-seeking
would portray them as weak and dependent, as well as
subject to control by health care providers, noting that “men
believed that ‘real men’ deal with personal problems on their
own, instead of asking help from other people.”86 However,
once on ART, men’s health and appearance improved and
they felt publicly able to share their HIV-positive serostatus,
which in turn won them support, approval and admiration,
becoming role models for breaking the secrecy and stigma
surrounding HIV.87 Other studies found that men were
particularly critical of serodiscordant couple interventions,
as couples counseling puts “the man on trial.” As one man
put it: “It is as if you are before a court, as you know women can get
authority over the man when other people are there...So your wife may
ask you how the disease came about. So you have to reveal the extra
affairs….”88 Providing sex-segregated counseling may be
more effective.89

Questions for Implementation Science
■■ How

can peer support be effectively provided for
men and how does it differ from a peer support
model for women?

Viral Suppression
ART adherence is critical to achieving viral suppression.
Additional factors such as drug resistance, drug interactions
and biological differences may also be subject to genderrelated challenges in achieving viral suppression.
Women may be at greater risk for viral drug resistance or
transmitting drug resistant strains due to the temporary use
of antiretrovirals to reduce vertical transmission. Further
evaluation is needed to understand these risks. While it is
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clear that those who go on ARV therapy for their own
treatment needs should not interrupt treatment,90 treatment
interruption for women who are on ART to prevent
perinatal transmission rather than for their own health
needs is the subject of an ongoing clinical trial (PROMISE),
with results expected in 2017. “The risk for maternal
health of stopping…maternal triple ARV prophylaxis
after breastfeeding cessation is unknown”91 – especially if
a woman living with HIV has multiple pregnancies. WHO
recommendations for Option B+, i.e., lifelong treatment for
pregnant women, may reduce stopping and re-starting ART
which can carry increased risk for mortality and morbidity.

Box 3

Results to Watch for
A number of ongoing efforts are looking at gender
dynamics in HIV treatment. Major initiatives with results to
watch for include:
• Key Barriers to Women’s Access to Treatment: Making
‘Fast-Track’ a Reality: This collaboration of UN Women,
ATHENA Network, AVAC, and Salamander Trust is
undertaking a global multi-stage review of the status
of access to antiretroviral therapy for women living
with HIV that includes a literature review, community
dialogues and country case studies. Expected late
2015.

Monitoring drug interactions can be increasingly complex in
populations that may also be using drugs for co-infections,
co-morbidities, or recreationally. Cross-hormonal treatment
protocols for transgender women and men may affect HIV
treatment success. While there are currently no documented
drug interactions among these medications and ARVs,
further research is needed.92 It is possible that ART may
lead to hormonal fluctuations and metabolic abnormalities
among transgender women taking hormonal medications
and close monitoring is needed.93

• Supporting Operational AIDS Research (Project
SOAR): Population Council and partners are
determining whether a community mobilization
intervention can effectively change gender norms
at the community level, and whether reductions in
harmful gender norms contribute to better health
service utilization, in particular services along the HIV
care and treatment continuum. Expected 2018.
• STRIVE Research Consortium: A six-year consortium
investigating the social norms and inequalities that
drive HIV, including: gender inequality and violence,
poor livelihood options, alcohol and drinking norms
and stigma and considerations. Ongoing projects
are taking place in India, South Africa and Tanzania
through 2018.

There May be Sex Differences in ART Efficacy
Access to treatment by sex has been disaggregated in a
number of studies. However, few studies have analyzed
sex differences. Studies to date have not shown differences
in virologic efficacy of ART by sex,94 although a number
have suggested that sex may influence the frequency,
presentation, and severity of selected ARV-related adverse
events.95 One study found differences in virologic failure
(i.e., ART fails to suppress and sustain viral load to less than
200 copies/mL) by sex, with women having an advantage
over men.96 Another study found that women were more
likely to have viral suppression and better ART outcomes97
while other research found that women were in better
clinical condition than men.98 “Although data are limited,
there is evidence that women may metabolize and respond
to specific medications, including ARV drugs, differently
than men.”99 In some studies, however, women experience
more adverse drug reactions than men.100

• Accelerating Children’s HIV/AIDS Treatment Initiative
(ACT): U.S. President’s Emergency Plan for AIDS
Relief (PEPFAR) and the Children’s Investment Fund
Foundation (CIFF) launched this two-year initiative to
double the number of children receiving ART across
ten priority African countries. Expected 2016.

load but with less of a CD4 cell increase than men. Women
started treatment at a less advanced disease stage but women
lost their immunological advantage over men despite a better
virological treatment response. In addition, men were better
informed about the use of ART.103 Other studies have found
that men are disadvantaged in ART due to differences in
body weight compared to dose.104

d’Arminio Monforte et al., 2013 notes “[a]lthough published
data suggest that there are no significant differences in ART
efficacy between women and men, it must be emphasized
that this is a conclusion drawn from a limited evidence
base.”101 ARVs are administered at fixed dosages that do
not take into account the different body weight, etc. of each
sex.102 A study in Tanzania in which 70% of the 234 patients
were women found that after one year of standard ART,
a higher proportion of females had an undetectable viral

The potential role of sex differences in HIV disease
progression and treatment response is an understudied
area of inquiry,105 with women under-represented in clinical
trials.106 A review of forty randomized controlled trials for
18 new drug applications for antiretroviral therapy submitted
to the U.S. Food & Drug Administration (FDA) between
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on women and their children: a study of 1,453 patients
in Uganda on the impact of requiring patients to disclose
their HIV status and have a “treatment buddy” or “medical
companion” to access ARV therapy found that 41% of the
women chose a child as their medical companion versus
14% of the men. Individuals with limited networks may
delay enrolling in or may drop out of care when treatment
support “buddies” are required.113

START is Just the Beginning: Moving
Forward in Ensuring Gender-Equitable
ART
Given the myriad ways that gender norms impact
antiretroviral treatment access and adherence, it is crucial
that HIV treatment programming recognize and address
gender issues in order to achieve the 90-90-90 goals which
seek to increase the numbers of people who know their
status, enroll and sustain ART treatment and achieve viral
suppression. If gender dynamics are not addressed within
treatment programming and policy, efforts to increase
treatment coverage will be undermined.

© 2012 Uganda National Volunteers Link, Courtesy of Photoshare

2000 and 2008 found that only 20% of trial participants
were women.107 Even when women are included, sexspecific analysis of the data is rarely undertaken.108 No
studies have addressed the possible interactions between
ART and sexual hormones in both men and women,
including pre, peri or post-menopause.109 At a minimum,
“research data should be disaggregated by sex to ensure
opportunities for [sex- and] gender-based analysis….”110

Now that the Strategic Timing of Antiretroviral Treatment
(START) study has shown substantially improved outcomes
for early treatment initiation,114 Kavanaugh et al. argue
that states’ “core minimum obligations now include
access to early ART for both individual and collective
benefit. Governments can now reasonably be expected
to enable early viral suppression through human rightsbased interventions….”115 These efforts must take into
consideration the issue of autonomy that women living
with HIV have consistently raised with respect to healthcare
decision-making, including whether and when to start
treatment. “Despite potential individual and public health
benefits for women living with HIV, the decision to begin
treatment for HIV is a deeply personal decision that reflects
a variety of private, contextual and structural factors.”116

Priority Actions for Implementation Science
■■ Analyze

gender and sex differences in clinical
data
——Enroll more women in clinical trials and conduct
more gender analyses of the data in order to
identify potential sex differences in antiretroviral
efficacy and in ART impact on cardiovascular
and other noncommunicable diseases affecting
those living with HIV.
——Carry

out further research on the effect of ART
on hormonal medications and vice versa.

Above All, ART Programming Must
Include Respect for Human Rights

Although there is a growing understanding and
documentation of how gender impacts HIV treatment,
there remain few evaluated interventions demonstrating
what works to overcome these gender-related barriers.
A number of questions and concerns remain: how will
access to ART be prioritized? How will treatment be
financed? How can ART be equitably accessible? How will
gender dynamics be addressed in ensuring access? Most
importantly, how can ART availability and accessibility
be partnered with informed consent about the risks and
benefits of treatment so that all people living with HIV may
decide for themselves how best to stay healthy and live full,
productive lives?

Expanding access to ART while considering equity and
human rights is urgently needed.111 WHO’s 2013 guidelines
note “human rights and ethical principles should guide…
national treatment policies to ensure that they are equitable
and meet the specific needs of all beneficiaries.”112 Requiring
people living with HIV to disclose their serostatus to sexual
partners and/or community members in order to receive
treatment, care or support is a human rights violation.
Similarly, coercing women to accept contraception in
order to access treatment violates women’s rights to make
their own fertility choices. While “treatment buddies” can
be supportive, requiring a treatment buddy or medical
companion to access ARV therapy may place undue burdens
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The photographs in this material are used for illustrative purposes only;
they do not imply any particular health status, attitudes, behaviors, or
actions on the part of any person who appears in the photographs.
Suggested citation: Croce-Galis M, J. Gay and K. Hardee. 2015. Gender
Considerations Along the HIV Treatment Cascade: An Evidence Review
with Priority Actions. Washington DC: Population Council and What
Works Association, Inc.
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